AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Thermo Fisher: UBS downgrades to 'Neutral' Rating, The Target Price is $460
ByAinvest
Wednesday, Jul 9, 2025 10:00 am ET1min read
UBS downgrades 'Neutral' rating on Thermo Fisher(TMO), compare with the 'Buy' previously.
The target price is $460, compare with $500 previously.
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-07-09 | UBS | Downgrades | Neutral | Buy | $460 | $500 |
| 2025-07-08 | Evercore ISI Group | Maintains | Outperform | Outperform | $480 | $500 |
| 2025-06-24 | Barclays | Maintains | Equal-Weight | Equal-Weight | $450 | $475 |
[Company Profile] Thermo Fisher Scientific Inc. is a Delaware corporation. The company is the world leader in serving science. The company Mission is to enable customers to make the world healthier, cleaner and safer. The company serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet